Continuity in Methylphenidate Treatment of Adults With Attention-Deficit/Hyperactivity Disorder
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although stimulant therapy is commonly discontinued early in adults with attention-deficit/hyperactivity disorder (ADHD), the factors that contribute to continuity of stimulant therapy remain largely unknown. OBJECTIVE: To (1) compare the continuity of methylphenidate (MPH) therapy among adults who use immediate-release methylphenidate (IR-MPH) for ADHD with adults who use extended-release methylphenidate (ER-MPH) formulations, and (2) examine some of the methodological issues involved in research with administrative claims for ADHD. METHODS: An analysis of pharmacy and medical claims for 75 US managed care plans representing approximately 55 million beneficiaries for dates of service from January 1, 2000 through December 31, 2004. Patients had to be adults (aged 18 to 64 years) who had 1 or more outpatient medical claims for ADHD (International Classification of Diseases, Ninth Revision, Clinical Modification code 314.xx) during the study period and who had initiated ER-MPH or IR-MPH treatment for ADHD. The study cohorts did not have a pharmacy claim for MPHs, amphetamines, pemoline, or atomoxetine for 6 months preceding the first (index) MPH pharmacy claim. Stimulant treatment episodes were defined to start on the index date and terminate on the last date supplied of the index medication. Episodes of treatment were also defined as terminated if there was a gap of > or =30 days between the end of the days supplied on the pharmacy claim and the date of the next pharmacy claim for the index medication. RESULTS: Less than one third (30.0%) of the adult patients who were prescribed MPH had 1 or more medical claims with a diagnosis code for ADHD. For the adult MPH patients with at least 1 medical claim with a diagnosis code for ADHD, the patients who initiated therapy with ER-MPH (N = 2,833) were significantly younger, were more likely to be male, and were less likely to be treated by a psychiatrist than were the patients who initiated therapy with IR-MPH (N = 2,289). Only 50.5% (n = 1,156) of IR-MPH patients and 61.4% (n = 1,739) of ER-MPH patients had more than 1 pharmacy claim for the index MPH medication. Adults treated with ER-MPH also had a significantly longer median duration of treatment with the index medication (ER-MPH: 68 days, 95% confidence interval [CI], 65-71 days vs. IR-MPH 39 days, 95% CI, 33-52 days). Controlling for group differences in age, gender, treatment by a psychiatrist, recently prescribed psychotropic medications, treated mental disorders, emergency mental health treatment, and inpatient mental health care, ER-MPH initiation was associated with an average 27% longer duration of treatment than with IR-MPH (survival time ratio: 1.27, 95% CI, 1.20-1.35). CONCLUSION: In management of adult ADHD, use of ER-MPH formulations was associated with a longer median duration of the initially prescribed medication than was use of IR-MPH. It is unknown whether the observed absolute unadjusted difference of 29 days in median length of therapy is clinically important.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interventions to Enhance Patient Adherence to Medication Prescriptions: Scientific Review
McDonald, H. P., Garg, A. X., & Haynes, R. B. (2002) · JAMA · doi:10.1001/jama.288.22.2868 · Cited by 1,176
Tamblyn, R., Lavoie, G., Petrella, L., & Monette, J. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00234-h · Cited by 577
Stimulant treatment over five years: adherence, effectiveness, and adverse effects
Charach, A., Ickowicz, A., & Schachar, R. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200405000-00009 · Cited by 315
Kirking, D. (1996) · Journal of Pharmacoepidemiology · doi:10.1300/j055v05n01_02 · Cited by 24
Cited by
Review of Medication Adherence in Children and Adults with ADHD
Adler, L. D., & Nierenberg, A. A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.01.2112 · Cited by 295
Schein, J., Adler, L. A., Childress, A., Gagnon-Sanschagrin, P., Davidson, M., Kinkead, F., Cloutier, M., Guérin, A., & Lefebvre, P. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.21290 · Cited by 56
Optimal management of ADHD in older adults
Torgersen, T., Gjervan, B., Lensing, M. B., & Rasmussen, K. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s59271 · Cited by 42
“In addition to the limiting factors discussed above, there are more general factors which may reduce the effect of drug therapy, like poor compliance to medication and lack of continuity of medication.(87) In addition, the high prevalence of comorbid psychiatric disorders, inefficient compensatory strategies, and mala…”
BackgroundDuration of effect of oral long-acting stimulant medications for ADHD throughout the day
Brams, M., Moon, E., Pucci, M., & López, F. A. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.488553 · Cited by 30
Psychopharmacological Treatment of ADHD in Adults Aged 50+: An Empirical Study
Lensing, M. B., Zeiner, P., Sandvik, L., & Opjordsmoen, S. (2015) · Journal of Attention Disorders · doi:10.1177/1087054714527342 · Cited by 18
Metadata
- Authors
- Olfson, M., Marcus, S. C., Zhang, H. F., & Wan, G. J.
- Venue
- Journal of Managed Care Pharmacy
- Publisher
- Academy of Managed Care Pharmacy
- Published
- 2007-09
- Volume
- 13
- Issue
- 7
- Pages
- 570-577
- ISSN
- 1083-4087 (ISSN-L)
- 1944-706X
- OpenAlex
- W29556339
- Cited by
- 48
- References
- 4
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Continuity in Methylphenidate Treatment of Adults With Attention-Deficit/Hyperactivity Disorder. https://app.cochat.ai/papers/10.18553/jmcp.2007.13.7.570
- The paper
- Olfson, M., Marcus, S. C., Zhang, H. F., & Wan, G. J. (2007). Continuity in Methylphenidate Treatment of Adults With Attention-Deficit/Hyperactivity Disorder. Journal of Managed Care Pharmacy. https://doi.org/10.18553/jmcp.2007.13.7.570
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.